TriSalus today said it appointed Steven Katz as chief medical officer.
Katz will be responsible for overseeing the company’s clinical development strategy in the treatment of solid tumors. He has served as TriSalus’s chief medical advisor and chairperson of its scientific advisory board since 2018.
“We are thrilled to have Steven join TriSalus as a member of our leadership team and one who will advance our goal of improving outcomes for patients with solid pancreatic and liver tumors,” president and CEO Mary Szela said.
Get the full story on our sister site, Drug Delivery Business News.